TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT04056936

Intervention type: PROCEDURE
Intervention: Frenotomy
Description: To map the severity determining any possible consequences a tongue-tie may have for breastfeeding and infant nutrition we will follow-up a cohort of tongue-tied infants to register if the feeding, growth, thriving and speech of the infant/child is affected by a tongue-tie.
Study: NCT03385070

Intervention type: DIAGNOSTIC_TEST
Intervention: Lens examination
Description: The presence of cortical lens opacity was biomicroscopically examined by two researchers using the diffuse, direct, Scheimpflug and retroillumination from the fundus methods.

Intervention type: DIAGNOSTIC_TEST
Intervention: Lens examination
Description: The presence of cortical lens opacity was biomicroscopically examined by two researchers using the diffuse, direct, Scheimpflug and retroillumination from the fundus methods.

Intervention type: DIAGNOSTIC_TEST
Intervention: Lens examination
Description: The presence of cortical lens opacity was biomicroscopically examined by two researchers using the diffuse, direct, Scheimpflug and retroillumination from the fundus methods.
Study: NCT01308957

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Omega-3 fatty acids
Description: 4 grams per day for 24 weeks

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: corn oil
Description: 4 grams per day for 24 weeks
Study: NCT00823901

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Clindamycin Phosphate 1.2% And Tretinoin 0.025% Gel
Description: Applied on entire face (forehead, nose, cheeks, chin) once daily at night for 12 weeks

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo gel
Description: Applied placebo gel with no active medication to entire face (forehead, nose, cheeks, chin) once daily at night for 12 weeks
Study: NCT00186771

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Paired Pulse
Description: True treatment with rTMS over the temporoparietal cortex.

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Paired Pulse
Description: Sham treatment with rTMS over the temporoparietal cortex.
Study: NCT00503659

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Bronchial methacholine provocation
Description: A short five-breath dosimeter protocol using a five-step dilution schedule according to ATS guidelines (0.0625, 0.25, 1, 4, 16 mg/ml methacholine)

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Bronchial methacholine provocation
Description: A five-step protocol using a single dilution of 16 mg/ml methacholine (0.01, 0.1, 0.4, 0.8, 1.6 mg)
Study: NCT02052089

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: physiotherapy
Description: Physiotherapy is the treatment of a wide range of conditions and injuries to the body through the use of various forms of passive mobilisation, massage, electrotherapy and exercises.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: extracorporeal shockwave therapy
Description: Extracorporeal shockwave therapy (ESWT) is noninvasive procedure, and has been shown to be effective in the treatment of chronic tendon pathology in the elbow, shoulder and plantar fascia. Shock wave therapy is traditionally categorized as either low energy (\<0.2 mJ/mm2) or high energy (\>0.2 mJ/mm2). Rompe, et al have hypothesized that there is an overstimulation of nerve fibers, resulting in an immediate analgesic effect (hyperstimulation analgesia). Physical effects on cell permeability and induction of diffusible radicals have also been postulated to cause disruption of the tendon tissue, resulting in induction of a healing process.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: prolotherapy
Description: Prolotherapy has been defined as the iatrogenic stimulation of wound healing and tissue repair through the injection of an irritant solution into damaged ligaments and tendons. Prolotherapy solutions are purported to initiate an inflammatory cascade at the site of injection, which induces fibroblast proliferation and subsequent collagen synthesis, resulting in a tighter and stronger ligament or tendon. The primary mechanism of action of prolotherapy is to induce a small inflammatory response to promote adequate healing or more viable scar tissue formation that results in stronger fibrous tissue at the lateral epicondyle, which leads to improved function and reduced pain.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: platelet-rich plasma
Description: Platelet-rich plasma (PRP) is defined as an autologous concentration of human platelets in a small volume of plasma which is mechanically treated to increase the concentration of platelets compared to whole blood. The supraphysiological concentration of platelets will provide a locally increased concentration of growth factors and cytokines that are contained within the platelets themselves.Based on these concepts, it is believed that PRP can augment or stimulate healing with the same biologic healing process that normally occurs in the human body after injury.
Study: NCT04286698

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Complex decongestive physiotherapy
Description: MLD was administered 5 days a week for 4 weeks, with each session lasting 30 minutes \[25\]. Compression therapy was applied to the patients by wearing a compression mask (FM Velcro Fastener, LIPOELASTIC), made of polyamide, cotton, viscose, and elastane, that covered the submandibular region, the masseter region, and the neck. The compression mask is specifically designed for the healing and recovery of tissues after plastic and aesthetic surgeries. The patients were advised to wear the compression masks for at least 4-6 hours per day for 4 weeks and gradually increase wearing time according to their tolerance. The patients were asked to perform skin care by themselves. Skin care was applied using a low pH skin lotion to moisturize the skin. Neck, face/mimic, tongue, and posture exercises were performed by patients while the compression mask was worn and under the supervision of a physiotherapist, with 10 repetitions 5 times a week for 4 weeks.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Home program
Description: Self-MLD and exercises (neck, face/mimic, tongue, and posture exercises) were shown to the patients in this group. Self-MLD included self-administered lymph drainage of the axillary, posterior, lateral, and anterior neck areas; the pre- and retro-auricular regions; the lateral and anterior regions of the face; and the lower jaw region. Then the order is reversed back to the starting point \[3\]. A video of self-MLD and a text including exercise descriptions were shared with patients and their relatives to ensure that the self-MLD and exercises were performed accurately and regularly at home. Self-MLD was recommended to be applied once a day, and the exercises were advised to be performed for 10 repetitions each, 10 times a day for 4 weeks. The patients were called by phone during the second week after their first evaluation as a control and to motivate the patient for performing self-MLD and home exercises properly.
Study: NCT01184963

Intervention type: DIETARY_SUPPLEMENT
Group type: OTHER
Intervention: High protein diet
Description: High protein diet (30% protein, 40% carbohydrate, 30% lipid)

Intervention type: DIETARY_SUPPLEMENT
Group type: OTHER
Intervention: Normal protein diet
Description: Normal protein diet (15% protein, 55% carbohydrate, 30% lipid

Intervention type: DIETARY_SUPPLEMENT
Group type: OTHER
Intervention: Normal protein diet
Description: Normal protein diet (15% protein, 55% carbohydrate, 30% lipid
Study: NCT00002485

Intervention type: PROCEDURE
Intervention: psychosocial assessment and care

Intervention type: PROCEDURE
Intervention: psychosocial assessment and care
Study: NCT04324437

Intervention type: OTHER
Group type: OTHER
Intervention: eRAPID online symptom monitoring in lung cancer
Description: The eRAPID in lung cancer intervention is an online symptom monitoring system which provides tailored advice depending on the severity of symptoms reported. The system is integrated into the electronic medical record and results can be viewed by the medical team.
Study: NCT03356041

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Diabetic patients with neuropathy
Description: Lifestyle modification will be assessed using summary of diabetes self-care activity
Study: NCT00860093

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: After SWL treatment subjects will be randomized to receive either MPC-5971 or placebo. Two tablets of MPC-5971 or placebo will be taken orally twice a day (bid). This will give a daily dosage equal to 40 mEq of potassium, 20 mEq of magnesium and 60 mEq of citrate. MPC-5971 or placebo will be taken bid for 90 days beginning immediately after SWL treatment.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MPC-5971
Description: After SWL treatment subjects will be randomized to receive either MPC-5971 or placebo. Two tablets of MPC-5971 or placebo will be taken orally twice a day (bid). This will give a daily dosage equal to 40 mEq of potassium, 20 mEq of magnesium and 60 mEq of citrate. MPC-5971 or placebo will be taken bid for 90 days beginning immediately after SWL treatment.
Study: NCT03405246

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: KIDFIT HEALTHY
Description: KIDFIT Healthy intervention combines traditional in-person and electronic participant contacts.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: KIDFIT SAFE
Description: KIDFIT Safe group will be referred to the KIDFIT Safe website for monthly Homestyles Safe Guides about safe home environments for raising children and related material emailed monthly to the moms.
Study: NCT04425109

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: meal test response
Description: soy fermented versus non fermented meal test

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: meal test response
Description: soy fermented versus non fermented meal test
Study: NCT00830440

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: EndoBarrier Device
Description: NIH derived dietary, exercise and behavior modification 2005 guidelines. https://health.gov/dietaryguidelines/2005.asp and EndoBarrier Device for 12 weeks

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Diet & Lifestyle Counseling
Description: NIH derived dietary, exercise and behavior modification 2005 guidelines. https://health.gov/dietaryguidelines/2005.asp

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Diet & Lifestyle Counseling
Description: NIH derived dietary, exercise and behavior modification 2005 guidelines. https://health.gov/dietaryguidelines/2005.asp
Study: NCT02644655

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: CD19-specific chimeric antigen receptor
Description: Cyclophosphamide 500 mg - 2000 mg/m2 (day 2) with or without Fludarabine 30 mg/m2 /day, 4 days (day 6, 5, 4, 3); nCAR19-T transfusion：day 0(5×105/kg，1×106/kg，3×106/kg).
Study: NCT01553968

Intervention type: OTHER
Group type: OTHER
Intervention: Cycling
Description: 30 minutes of cycling at 50% of predetermined maximal performance

Intervention type: OTHER
Group type: OTHER
Intervention: Cycling
Description: 30 minutes of cycling at 50% of predetermined maximal performance
Study: NCT01446055

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: ResQ processed bone marrow sample
Description: Autologous bone marrow is processed with ResQ at point of care, prior to the transplantation
Study: NCT04100473

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Inhaled Human Insulin
Description: Dance 501 administered using the Dance 501 Inhaler

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Insulin Lispro (Humalog U-100)
Description: Lispro
Study: NCT00710827

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: NEBIDO
Description: Patients will receive 54 weeks of treatment with Nebido, 5 intramuscular injections of 4ml Nebido (at baseline, week 6, 18, 30, 42)

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: PLACEBO
Description: Patients will receive 54 weeks of treatment with placebo, 5 intramuscular injections of 4ml placebo (at baseline, week 6, 18, 30, 42)
Study: NCT01601483

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MC-1101
Description: 1% Ophthalmic Solution TID

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: MC-1101 Vehicle
Description: Ophthalmic solution, TID
Study: NCT01859286

Intervention type: OTHER
Intervention: standardized sign out process
Description: The intervention phase included was the introduction of a standardized TOC (transfer of care) process, which occurred during April and May of 2012. TOC was done at a predefined location in each section of the emergency department (Medicine and Trauma). All participating residents were given a diagram detailing the central location and seating arrangement. The outgoing attending was designated to handle all distractions or disturbances that occurred during sign out. The most senior resident coming on to shift was designated the data resident. The data resident's role was to operate a centralized computer with the ED tracking board and EMR and review pending orders, vital signs and resulted labs and radiology reports after each patient was signed out. A brief pause was implemented to allow the oncoming team to ask any questions regarding that patient's care or course. The post TOC data form and protocol were identical to that of the control phase.
Study: NCT00813163

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PEP02
Description: 120 mg/m2, IV infusion for 90 minutes on day 1 of each 21 days as a treatment cycle.~Number of Cycles: until progression or unacceptable toxicity develops.
Study: NCT02863887

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Weight loss intervention
Description: The intervention will involve utilizing trained community health coaches to deliver the weight loss intervention. There will be 10 group based sessions conducted at each church over 6 months. Session frequency will be 4 weekly sessions (4) for the first month, bimonthly sessions for 2 months (4) and monthly sessions for 2 months (2). The study is based upon weight loss strategies that have been utilized in the Diabetes Prevention Program. The group sessions will be augmented by utilizing text messages. The text messages will be delivered weekly and three types of messages will be delivered: 1) lesson content, 2) motivational, 3) behavioral prompts.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Weight loss intervention
Description: The intervention will involve utilizing trained community health coaches to deliver the weight loss intervention. There will be 10 group based sessions conducted at each church over 6 months. Session frequency will be 4 weekly sessions (4) for the first month, bimonthly sessions for 2 months (4) and monthly sessions for 2 months (2). The study is based upon weight loss strategies that have been utilized in the Diabetes Prevention Program. The group sessions will be augmented by utilizing text messages. The text messages will be delivered weekly and three types of messages will be delivered: 1) lesson content, 2) motivational, 3) behavioral prompts.
Study: NCT03476330

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Quercetin (dietary supplement)
Description: Quercetin will be administered twice daily at an adjusted dose based on weight for a maximum total daily dose of 4000mg/day. If the patient is 70 kg or more, the dose will automatically be assigned at the maximum dose of 4000mg/day.
Study: NCT04248270

Intervention type: DRUG
Group type: OTHER
Intervention: 18F-PM-PBB3
Description: All scans will be acquired in pairs of 18F-florbetapir(18F-AV45) and/or18F-PM-PBB3 PET scans (if patient select), performed on separate days, and at least 2 days apart, with either scan performed first. The 18F-florbetapir and 18F-PM-PBB3 protocol will entail the inon of 5±2mCi of tracer followed by an uptake phase of 50 min during which time the state of the subject is not important. After 40 minutes, subjects will be positioned and 4 x 5 min frames of emission data will be collected right at 50 min after tracer injection. PET/MRI scans will precede this acquisition with a MRI scan for attenuation correction; PET-only scanners will perform a transmission scan following the emission scan.
Study: NCT00621647

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Quetiapine Fumarate

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Quetiapine Fumarate

Intervention type: DRUG
Group type: SHAM_COMPARATOR
Intervention: Placebo
Study: NCT01549054

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 10-mg dose of E5501 2G tablet
Description: Treatment A: Single 10-mg dose of E5501 2G tablet

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 10-mg dose of E5501 cyclodextrin oral solution
Description: Treatment B: Single 10-mg dose of E5501 cyclodextrin oral solution

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 10-mg dose of E5501-P21% powder
Description: Treatment C: Single 10-mg dose of E5501-P21% powder oral suspension

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 10-mg dose of E5501 lipid-based oral
Description: Treatment D: Single 10-mg dose of E5501 lipid-based oral suspension
Study: NCT02624765

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Digoxin (monotherapy)
Description: Oral or IV loading dose: 0.5 mg q 12 h (total 4 doses over 48 hours) followed by Oral maintenance dose: 0.25 mg-1mg/day

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Digoxin (monotherapy)
Description: Oral or IV loading dose: 0.5 mg q 12 h (total 4 doses over 48 hours) followed by Oral maintenance dose: 0.25 mg-1mg/day

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Sotalol (monotherapy)
Description: Oral dose: 80 mg TID or 120 mg BID (240 mg/day)

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Flecainide (monotherapy)
Description: Oral dose: 100 mg TID (300 mg/day)

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Digoxin (dual therapy)
Description: Oral or IV loading dose: 0.5 mg q 8 h (total 4 doses over 32 hours) followed by oral maintenance dose: 0.25 mg-1mg/day

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Digoxin (dual therapy)
Description: Oral or IV loading dose: 0.5 mg q 8 h (total 4 doses over 32 hours) followed by oral maintenance dose: 0.25 mg-1mg/day

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Sotalol (dual therapy)
Description: Oral dose: 160 mg BID (320 mg/day)

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Flecainide (dual therapy)
Description: Oral dose:100 mg TID (300 mg/day)
Study: NCT01526070

Intervention type: DRUG
Intervention: Intravitreal injection of Aflibercept
Study: NCT03798093

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Umbilical Cord Milking
Description: At delivery, the umbilical cord is grasped, and blood is pushed toward the infant 4 times before the cord is clamped. This procedure infuses a placental transfusion of blood into the infant and can be done in 15-20 seconds.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Early Cord Clamping
Description: The umbilical cord is clamped within 60 seconds of delivery.
Study: NCT03095430

Intervention type: DEVICE
Intervention: Monitoring
Description: Monitoring
Study: NCT01000636

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Metvix PDT
Description: Methyl aminolevulinate cream will be applied for 3 hours on the whole target field.~The target field will then be exposed to red light using Aktilite 128 lamp.
Study: NCT01725542

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Asunaprevir, Daclatasvir, Ribavirin and Peginterferon alfa-2a
Study: NCT04005053

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: N-acetyl cysteine
Description: 3600 or 5400 mg/day N-acetyl cysteine

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: N-acetyl cysteine
Description: 3600 or 5400 mg/day N-acetyl cysteine

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo oral tablet
Description: Placebo
Study: NCT04616976

Intervention type: BIOLOGICAL
Intervention: convalescent plasma
Description: convalescent plasma was get from the patients who recovery from COVID-19
Study: NCT02688283

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Nutrient cluster
Description: Test cluster is an optimized savory cluster made through a proprietary baking process combined with slow digestible carbohydrates and fiber

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Nutrient cluster
Description: Test cluster is an optimized savory cluster made through a proprietary baking process combined with slow digestible carbohydrates and fiber

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Nutrient cluster
Description: Test cluster is an optimized savory cluster made through a proprietary baking process combined with slow digestible carbohydrates and fiber
Study: NCT02860663

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Vitamin D3
Description: 10 ug/d of vitamin D3 for 6 weeks

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Vitamin D2
Description: 10 ug/d of vitamin D3 for 6 weeks

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: 25OHD
Description: 10 ug/d of vitamin D3 for 6 weeks
Study: NCT03541096

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Winter Swimming
Description: Supervised Winter Swimming in Copenhagen
Study: NCT01446055

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Ficoll conventional cell processing method
Description: Comparison of different cell processing methods
Study: NCT02943434

Intervention type: OTHER
Group type: OTHER
Intervention: Processed food
Description: This is examining the effects of processed foods on diet-induced thermogenesis.

Intervention type: OTHER
Group type: OTHER
Intervention: Processed food
Description: This is examining the effects of processed foods on diet-induced thermogenesis.
Study: NCT02096302

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Infant Formula with a novel probiotic CECT7210
Description: Bottle-feeding with a new infant formula enriched with probiotic CECT7210 during the first 3 months of life.

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Standard formula
Description: Standard formula without probiotics
Study: NCT02346058

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Esarin Gel
Study: NCT04603599

Intervention type: DIAGNOSTIC_TEST
Intervention: serum soluble L1CAM (sL1CAM)
Description: blood sample

Intervention type: DIAGNOSTIC_TEST
Intervention: serum soluble L1CAM (sL1CAM)
Description: blood sample

Intervention type: DIAGNOSTIC_TEST
Intervention: serum soluble L1CAM (sL1CAM)
Description: blood sample
Study: NCT03541096

Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Control group
Description: No winter swimming activities.